These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37418539)

  • 21. Novel immunomodulatory drugs and neo-substrates.
    Gao S; Wang S; Song Y
    Biomark Res; 2020; 8():2. PubMed ID: 31938543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanisms of thalidomide and its derivatives.
    Ito T; Handa H
    Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.
    Cheng J; Guo J; North BJ; Tao K; Zhou P; Wei W
    Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):138-159. PubMed ID: 30602127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
    Sievers QL; Petzold G; Bunker RD; Renneville A; Słabicki M; Liddicoat BJ; Abdulrahman W; Mikkelsen T; Ebert BL; Thomä NH
    Science; 2018 Nov; 362(6414):. PubMed ID: 30385546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cereblon modulators: Low molecular weight inducers of protein degradation.
    Chamberlain PP; Cathers BE
    Drug Discov Today Technol; 2019 Apr; 31():29-34. PubMed ID: 31200856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3.
    Shih PC; Naganuma M; Tsuji G; Demizu Y; Naito M
    Bioorg Med Chem; 2023 Nov; 95():117507. PubMed ID: 37922656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Discovery of the target for immunomodulatory drugs (IMiDs)].
    Ito T; Ando H; Handa H
    Rinsho Ketsueki; 2016 May; 57(5):556-62. PubMed ID: 27263779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SuFEx-based chemical diversification for the systematic discovery of CRBN molecular glues.
    Carter TR; Milosevich N; Dada L; Shaum JB; Barry Sharpless K; Kitamura S; Erb MA
    Bioorg Med Chem; 2024 Apr; 104():117699. PubMed ID: 38608634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases.
    Zhou L; Xu G
    J Mol Biol; 2022 Mar; 434(5):167457. PubMed ID: 35045330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. UBE2G1 governs the destruction of cereblon neomorphic substrates.
    Lu G; Weng S; Matyskiela M; Zheng X; Fang W; Wood S; Surka C; Mizukoshi R; Lu CC; Mendy D; Jang IS; Wang K; Marella M; Couto S; Cathers B; Carmichael J; Chamberlain P; Rolfe M
    Elife; 2018 Sep; 7():. PubMed ID: 30234487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IKZF2 Degradation: It's Time to Take into Account it When Designing Cereblon-Based PROTACs.
    Li M
    Chembiochem; 2024 Aug; 25(16):e202400365. PubMed ID: 38802326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon.
    Nguyen TV; Lee JE; Sweredoski MJ; Yang SJ; Jeon SJ; Harrison JS; Yim JH; Lee SG; Handa H; Kuhlman B; Jeong JS; Reitsma JM; Park CS; Hess S; Deshaies RJ
    Mol Cell; 2016 Mar; 61(6):809-20. PubMed ID: 26990986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation.
    Xie H; Li C; Tang H; Tandon I; Liao J; Roberts BL; Zhao Y; Tang W
    J Med Chem; 2023 Feb; 66(4):2904-2917. PubMed ID: 36749666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation.
    Norris S; Ba X; Rhodes J; Huang D; Khambatta G; Buenviaje J; Nayak S; Meiring J; Reiss S; Xu S; Shi L; Whitefield B; Alexander M; Horn EJ; Correa M; Tehrani L; Hansen JD; Papa P; Mortensen DS
    J Med Chem; 2023 Dec; 66(23):16388-16409. PubMed ID: 37991844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Target protein localization and its impact on PROTAC-mediated degradation.
    Simpson LM; Glennie L; Brewer A; Zhao JF; Crooks J; Shpiro N; Sapkota GP
    Cell Chem Biol; 2022 Oct; 29(10):1482-1504.e7. PubMed ID: 36075213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein Degradation via CRL4
    Hansen JD; Condroski K; Correa M; Muller G; Man HW; Ruchelman A; Zhang W; Vocanson F; Crea T; Liu W; Lu G; Baculi F; LeBrun L; Mahmoudi A; Carmel G; Hickman M; Lu CC
    J Med Chem; 2018 Jan; 61(2):492-503. PubMed ID: 28358507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Recent topics in IMiDs and cereblon].
    Ito T; Handa H
    Rinsho Ketsueki; 2017; 58(10):2067-2073. PubMed ID: 28978850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cyclimids: Degron-inspired cereblon binders for targeted protein degradation.
    Ichikawa S; Payne NC; Xu W; Chang CF; Vallavoju N; Frome S; Flaxman HA; Mazitschek R; Woo CM
    Cell Chem Biol; 2024 Jun; 31(6):1162-1175.e10. PubMed ID: 38320555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cereblon neo-substrate binding mimics the recognition of the cyclic imide degron.
    Heim C; Spring AK; Kirchgäßner S; Schwarzer D; Hartmann MD
    Biochem Biophys Res Commun; 2023 Feb; 646():30-35. PubMed ID: 36701892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.